Glenmark Pharmaceuticals Limited
GLENMARK
株式のランク
#2734
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
株価
$24.39
最終同期: 2026-10-19
時価総額
$6.88B
変化（1日）
-1.20%
変化（1年）
15.69%
国
IN
取引 Glenmark Pharmaceuticals Limited (GLENMARK)
カテゴリー
Healthcare
Glenmark Pharmaceuticals Limited（GLENMARK）の配当利回りの履歴
Glenmark Pharmaceuticals Limited（銘柄コード: GLENMARK）の配当利回り（TTM）は2024-03-31時点で0.42%です。
過去5年間の平均配当利回り: 0.58%
過去5年間の平均配当利回り: 0.58%
Glenmark Pharmaceuticals Limited（GLENMARK）の2004から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
| 年 | 配当利回り | 変化 |
|---|---|---|
| 2026 (TTM) | 0.22% | 29.41% |
| 2025 | 0.17% | -59.52% |
| 2024 | 0.42% | -59.62% |
| 2023 | 1.04% | 40.54% |
| 2022 | 0.74% | 37.04% |
| 2021 | 0.54% | -54.24% |
| 2020 | 1.18% | 218.92% |
| 2019 | 0.37% | -15.91% |
| 2018 | 0.44% | 57.14% |
| 2017 | 0.28% | -6.67% |
| 2016 | 0.30% | 0.00% |
| 2015 | 0.30% | -26.83% |
| 2014 | 0.41% | -19.61% |
| 2013 | 0.51% | 240.00% |
| 2012 | 0.15% | -6.25% |
| 2011 | 0.16% | -5.88% |
| 2010 | 0.17% | 0.00% |
| 2009 | 0.00% | -100.00% |
| 2008 | 0.17% | 21.43% |
| 2007 | 0.14% | -70.83% |
| 2006 | 0.48% | 92.00% |
| 2005 | 0.25% | -73.12% |
| 2004 | 0.93% | 0.00% |
類似企業または競合他社の配当利回り（TTM）
| 企業 | 配当利回り | 国 |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 0.91% |
IN
|
